Advertisement
Advertisement
DNTH
Dianthus Therapeutics, Inc. Common Stock
86.03
USDSponsored
+3.02
+3.64%
Nov 06, 15:59 UTC -5
Closed
After-Market
89.23
+3.20
+3.72%
Dianthus Therapeutics, Inc. Common Stock (DNTH) Earnings
DNTH Earnings Reports
Positive Surprise Ratio
DNTH beat 22 of 33 last estimates.
67%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$374.92K
/-$1.09
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
+32.01%
/-23.78%
Dianthus Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, DNTH reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -1.00 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 453.53 thousand, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.09 USD, with revenue projected to reach 374.92 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were Dianthus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Dianthus Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Dianthus Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Dianthus Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for Dianthus Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Dianthus Therapeutics, Inc. Common Stock is expected to report EPS of -$1.09 and revenue of $374.92K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.